STAT+: Sarepta Therapeutics CEO Doug Ingram will retire after a tumultuous decade

STAT News · Feb 26, 2026 · Collected from RSS

Full Article

Under Ingram, new treatments were approved and the company’s value soared — then collapsed Sarepta Therapeutics CEO Doug Ingram at the company’s offices in Cambridge, Mass.Aram Boghosian for STAT By Jason MastFeb. 25, 2026 General Assignment Reporter Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason on Signal at JasonMast.05. Sarepta Therapeutics’ CEO Doug Ingram said Wednesday he would retire after a tumultuous decade in which he turned the biotech into a $15 billion company by pushing three different treatments for Duchenne muscular dystrophy to approval and then watched that value collapse amid investigations into the safety of its gene therapy and the emergence of superior versions of its other products. The company is currently searching for a successor. Ingram will retire by the end of the year, if a new CEO is not found before then. On an earnings call, Ingram said he was leaving because his wife and son were recently diagnosed with myotonic dystrophy, a form of muscular dystrophy that Sarepta started working on in 2024 through a new partnership. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe General Assignment Reporter Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason on Signal at JasonMast.05.